Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amir Alizadeh

Internal Medicine North Providence, RI Medical Doctor

NPI 1942333877 CMS profile 133176

1637 Mineral Spring Ave 107, North Providence, RI 02904

Open in the dashboard

General payments

$2,234

103 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amir Alizadeh of North Providence, RI is reported in the CMS Open Payments database as having received $2,234 across 103 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $429 21
2024 General $373 18
2023 General $493 24
2022 General $402 19
2021 General $280 11
2020 General $46 3
2019 General $211 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amir Alizadeh
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Amir Alizadeh were reported at $429. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Amir Alizadeh Internal Medicine median Middle half National median
2019 $211 $159 $48–$570 $163
2020 $46 $119 $33–$402 $114
2021 $280 $135 $37–$521 $132
2022 $402 $141 $42–$496 $149
2023 $493 $149 $45–$519 $160
2024 $373 $154 $47–$537 $164
2025 $429 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $470 25 payments
  2. AbbVie, Inc. $223 11 payments
  3. GlaxoSmithKline, LLC. $190 11 payments
  4. Novo Nordisk Inc $189 10 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $148 2 payments
  6. Lilly USA, LLC $133 6 payments
  7. Janssen Pharmaceuticals, Inc $126 6 payments
  8. Astellas Pharma US Inc $124 2 payments
  9. E.R. Squibb & Sons, L.L.C. $113 6 payments
  10. Abbott Laboratories $111 5 payments
  11. Other $407 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,134 102 payments
  2. Education $100 1 payment
Products named General payments · program years 2019–2025
  1. ELIQUIS Cardiovascular;Metabolic Disease $382 20 payments
  2. TRELEGY ELLIPTA $176 10 payments
  3. Ozempic $173 9 payments
  4. RYBELSUS $173 9 payments
  5. NURTEC ODT $149 7 payments
  6. MOUNJARO $133 6 payments
  7. VRAYLAR $131 6 payments
  8. COLOGUARD DNA CAPTURE REAGENTS $122 7 payments
  9. JARDIANCE $119 1 payment
  10. ELIQUIS Cardiovascular $113 6 payments
  11. Other $1,327 66 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 138 drugs

Part D claims

14,554

Median for Internal Medicine: 777

Drug cost

$613,205

Median for Internal Medicine: $73,373

Branded share of claims

13.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 185 $124,124
Ozempic Semaglutide Brand 115 $114,558
Jardiance Empagliflozin Brand 52 $34,934
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 36 $34,281
Xarelto Rivaroxaban Brand 25 $23,806
Januvia Sitagliptin Phosphate Brand 22 $23,006
Trulicity Dulaglutide Brand 21 $19,130
Tradjenta Linagliptin Brand 23 $15,469
Spiriva Handihaler Tiotropium Bromide Brand 21 $14,359
Atorvastatin Calcium Generic 1,197 $12,359

The 10 drugs with the highest cost, of 138 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$138,996

Of which drugs: $67

Medicare patients

215

Average age 78

Services billed

2,203

116 women, 99 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Diabetes 35%
Depression 29%
Cancer 28%
Ischemic heart disease 25%
Atrial fibrillation 18%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 15 72 $66
Vaccine for influenza for injection into muscle 90653 Office 60 61 $1

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $35
  • PFIZER INC. $23
$58 185 —
VRAYLAR
  • AbbVie, Inc. $51
$51 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $28
$28 36 —
XARELTO
  • Janssen Pharmaceuticals, Inc $27
$27 25 —
NURTEC ODT
  • PFIZER INC. $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

103 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Rhode Island

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record